Display options
Cite
Zapka JM, Edwards HM, Chollette V, et al. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1965-73doi: 10.1158/1055-9965.EPI-14-0454.
Zapka, J. M., Edwards, H. M., Chollette, V., & Taplin, S. H. (2014). Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(10), 1965-73. https://doi.org/10.1158/1055-9965.EPI-14-0454
Zapka, Jane M, et al. "Follow-up to abnormal cancer screening tests: considering the multilevel context of care." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 23,10 (2014): 1965-73. doi: https://doi.org/10.1158/1055-9965.EPI-14-0454
Zapka JM, Edwards HM, Chollette V, Taplin SH. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1965-73. doi: 10.1158/1055-9965.EPI-14-0454. Epub 2014 Jul 29. PMID: 25073625; PMCID: PMC4191903.
Copy Download .nbib Format: NLM
Share it on

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1965-73. doi: 10.1158/1055-9965.EPI-14-0454. Epub 2014 Jul 29.

Follow-up to abnormal cancer screening tests: considering the multilevel context of care.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Jane M Zapka, Heather M Edwards, Veronica Chollette, Stephen H Taplin

Affiliations

  1. Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina. [email protected].
  2. Clinical Research Directorate/CMRP, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  3. Process of Care Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.

PMID: 25073625 PMCID: PMC4191903 DOI: 10.1158/1055-9965.EPI-14-0454

Abstract

The call for multilevel interventions to improve the quality of follow-up to abnormal cancer screening has been out for a decade, but published work emphasizes individual approaches, and conceptualizations differ regarding the definition of levels. To investigate the scope and methods being undertaken in this focused area of follow-up to abnormal tests (breast, colon, cervical), we reviewed recent literature and grants (2007-2012) funded by the National Cancer Institute. A structured search yielded 16 grants with varying definitions of "follow-up" (e.g., completion of recommended tests, time to diagnosis); most included minority racial/ethnic group participants. Ten grants concentrated on measurement/intervention development and 13 piloted or tested interventions (categories not mutually exclusive). All studies considered patient-level factors and effects. Although some directed interventions at provider levels, few measured group characteristics and effects of interventions on the providers or levels other than the patient. Multilevel interventions are being proposed, but clarity about endpoints, definition of levels, and measures is needed. The differences in the conceptualization of levels and factors that affect practice need empirical exploration, and we need to measure their salient characteristics to advance our understanding of how context affects cancer care delivery in a changing practice and policy environment.

©2014 American Association for Cancer Research.

References

  1. Med Care. 2013 Apr;51(4):307-14 - PubMed
  2. Health Aff (Millwood). 2010 Apr;29(4):614-21 - PubMed
  3. Am J Prev Med. 2008 Jul;35(1 Suppl):S34-55 - PubMed
  4. Med Care Res Rev. 2003 Sep;60(3):294-331 - PubMed
  5. Can Fam Physician. 2012 Jan;58(1):e22-31 - PubMed
  6. J Natl Cancer Inst Monogr. 2010;2010(40):3-10 - PubMed
  7. J Natl Cancer Inst Monogr. 2010;2010(40):104-10 - PubMed
  8. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1691-700 - PubMed
  9. Patient Educ Couns. 2004 Oct;55(1):32-9 - PubMed
  10. Am J Med Qual. 2012 Nov-Dec;27(6):458-66 - PubMed
  11. J Health Care Poor Underserved. 2011 Feb;22(1):83-100 - PubMed
  12. J Natl Cancer Inst Monogr. 2010;2010(40):81-9 - PubMed
  13. Arch Intern Med. 2010 Mar 22;170(6):521-8 - PubMed
  14. Health Aff (Millwood). 2013 Feb;32(2):357-67 - PubMed
  15. Women Health. 2010 Sep;50(6):580-97 - PubMed
  16. Cancer. 2008 Oct 15;113(8):1999-2010 - PubMed
  17. Curr Opin Oncol. 2002 Sep;14(5):505-11 - PubMed
  18. J Womens Health (Larchmt). 2012 Apr;21(4):393-400 - PubMed
  19. J Natl Cancer Inst. 2014 Jun 17;106(6):dju115 - PubMed
  20. Arch Intern Med. 2011 Aug 8;171(15):1335-43 - PubMed
  21. Am J Prev Med. 2008 Jul;35(1 Suppl):S56-66 - PubMed
  22. CA Cancer J Clin. 2008 May-Jun;58(3):161-79 - PubMed
  23. J Natl Cancer Inst Monogr. 2010;2010(40):38-57 - PubMed
  24. Cancer. 2004 Sep 1;101(5 Suppl):1239-50 - PubMed
  25. J Natl Cancer Inst Monogr. 2012 May;2012(44):127-33 - PubMed
  26. Am J Prev Med. 2009 Jul;37(1):1-7 - PubMed
  27. J Natl Cancer Inst Monogr. 2010;2010(40):31-7 - PubMed
  28. Ann Intern Med. 2013 Jan 15;158(2):77-83 - PubMed
  29. J Natl Cancer Inst. 2013 Feb 6;105(3):175-201 - PubMed
  30. J Natl Cancer Inst Monogr. 2012 May;2012(44):86-99 - PubMed
  31. J Womens Health (Larchmt). 2013 Feb;22(2):159-66 - PubMed
  32. J Natl Cancer Inst Monogr. 2012 May;2012(44):20-31 - PubMed
  33. Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):4-13 - PubMed
  34. Health Aff (Millwood). 2011 Mar;30(3):439-45 - PubMed
  35. Lancet Oncol. 2008 Mar;9(3):222-31 - PubMed
  36. Dis Colon Rectum. 2006 Jul;49(7):1002-10 - PubMed
  37. J Natl Cancer Inst Monogr. 2010;2010(40):11-7 - PubMed
  38. Br J Gen Pract. 1999 Mar;49(440):223-9 - PubMed
  39. BMC Med Inform Decis Mak. 2009 Dec 09;9:49 - PubMed
  40. J Gen Intern Med. 2009 Jun;24(6):702-9 - PubMed
  41. J Natl Cancer Inst Monogr. 2012 May;2012(44):11-9 - PubMed
  42. Health Aff (Millwood). 2013 Feb;32(2):250-8 - PubMed
  43. Cancer. 1999 Dec 1;86(11):2378-90 - PubMed
  44. Med Care. 1998 Mar;36(3):397-410 - PubMed
  45. J Health Care Poor Underserved. 2010 Feb;21(1 Suppl):71-94 - PubMed
  46. J Gen Intern Med. 2010 Jun;25(6):575-80 - PubMed
  47. CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41 - PubMed
  48. Cancer Causes Control. 2010 Nov;21(11):1931-40 - PubMed
  49. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1620-8 - PubMed
  50. JAMA Intern Med. 2013 Apr 22;173(8):702-4 - PubMed
  51. MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):41-5 - PubMed
  52. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1709-15 - PubMed
  53. J Natl Cancer Inst Monogr. 2010;2010(40):25-30 - PubMed
  54. Milbank Q. 2001;79(2):281-315 - PubMed
  55. J Natl Cancer Inst Monogr. 2010;2010(40):58-71 - PubMed
  56. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1069-77 - PubMed
  57. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1629-38 - PubMed
  58. BMJ. 2009 Jul 21;339:b2535 - PubMed
  59. Cancer. 2010 Feb 15;116(4):913-21 - PubMed
  60. Cancer. 2004 Sep 1;101(5 Suppl):1188-200 - PubMed
  61. Am J Prev Med. 2008 Jul;35(1 Suppl):S6-9 - PubMed
  62. Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):957-64 - PubMed
  63. J Natl Cancer Inst. 1987 Aug;79(2):389-400 - PubMed
  64. J Natl Cancer Inst Monogr. 2012 May;2012(44):34-41 - PubMed
  65. Med Care. 2008 Jul;46(7):692-700 - PubMed
  66. J Natl Cancer Inst Monogr. 2010;2010(40):18-24 - PubMed
  67. J Natl Cancer Inst Monogr. 2012 May;2012(44):49-55 - PubMed
  68. Am J Prev Med. 2012 Jul;43(1):97-118 - PubMed
  69. J Natl Cancer Inst Monogr. 2012 May;2012(44):2-10 - PubMed
  70. J Gen Intern Med. 2014 Jun;29(6):894-910 - PubMed
  71. J Natl Cancer Inst Monogr. 2010;2010(40):72-80 - PubMed

MeSH terms

Publication Types

Grant support